Bwakura-Dangarembizi M, Chappell E, Kityo C, Anena DL, et al. Switch to injectable cabotegravir-rilpivirine given every 8 weeks in adolescents living with HIV with virological suppression in sub-Saharan Africa (LATA): a randomised, open-label, multicentre, 96-week non-inferiority trial. Lancet 2026 Sep 17:S0140-6736(26)01537-0. doi: 10.1016/S0140-6736(26)01537.
PMID: 42753775